Counterpoint Mutual Funds LLC Makes New Investment in Azenta, Inc. $AZTA

Key Points

• Counterpoint Mutual Funds LLC acquired a new stake in Azenta, Inc., purchasing 11,131 shares valued at approximately $343,000 during the second quarter.
• Multiple institutional investors have increased their holdings in Azenta, with Deutsche Bank AG raising its stake by 28.5% in the fourth quarter.
• Azenta's stock has a current price target consensus of $35.75, with two analysts recommending a Buy rating and three suggesting Hold, amid a 1 year high of $55.63 and a low of $23.91.

Counterpoint Mutual Funds LLC bought a new position in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,131 shares of the company's stock, valued at approximately $343,000.

Several other hedge funds have also recently modified their holdings of AZTA. Deutsche Bank AG raised its holdings in shares of Azenta by 28.5% in the 4th quarter. Deutsche Bank AG now owns 4,199 shares of the company's stock worth $210,000 after purchasing an additional 931 shares during the period. Millennium Management LLC raised its holdings in shares of Azenta by 19.8% in the 4th quarter. Millennium Management LLC now owns 108,175 shares of the company's stock worth $5,409,000 after purchasing an additional 17,899 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Azenta by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 170,845 shares of the company's stock worth $8,542,000 after purchasing an additional 9,969 shares during the period. Alpha Wealth Funds LLC bought a new stake in shares of Azenta in the 4th quarter worth approximately $225,000. Finally, GAMMA Investing LLC raised its holdings in shares of Azenta by 4,054.6% in the 1st quarter. GAMMA Investing LLC now owns 65,019 shares of the company's stock worth $2,252,000 after purchasing an additional 63,454 shares during the period. Institutional investors own 99.08% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on AZTA. Stephens began coverage on shares of Azenta in a report on Tuesday, July 22nd. They issued an "equal weight" rating and a $35.00 price target on the stock. Raymond James Financial raised shares of Azenta from a "market perform" rating to an "outperform" rating and set a $35.00 target price on the stock in a report on Wednesday, August 6th. Finally, Evercore ISI set a $33.00 target price on shares of Azenta and gave the company an "in-line" rating in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $35.75.

Azenta Price Performance

Shares of AZTA stock opened at $29.81 on Thursday. The company's fifty day simple moving average is $30.81 and its two-hundred day simple moving average is $30.42. Azenta, Inc. has a 1 year low of $23.91 and a 1 year high of $55.63. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -12.32 and a beta of 1.65.

Azenta (NASDAQ:AZTA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.06. The firm had revenue of $143.94 million during the quarter, compared to analyst estimates of $149.64 million. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The business's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the business earned $0.14 EPS. Equities research analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current year.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.